Terminated
PHASE1, PHASE2
INTERVENTIONAL
NCT00819169
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
This is a multi-center, 2-part phase 1b/2 study of AMG 655 in combination with AMG 479 to be conducted in the United States and Spain. Part 1 is a dose escalation segment to identify a dose of AMG 655 in combination with AMG 479 that is safe and tolerable. Part 2 will evaluate the safety and estimate the efficacy of AMG 655 at the dose selected in Part 1 in combination with AMG 479 for the treatment of patients with advanced NSCLC (non-squamous histology; squamous histology), CRC, pancreatic cancer, ovarian cancer, and sarcoma.
Interventions
Name:
AMG 479
Type:
BIOLOGICAL
Description:
AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
Name:
AMG 655
Type:
BIOLOGICAL
Description:
AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.
Primary Outcomes
Measure:
Number of Participants With Dose-limiting Toxicities
TimeFrame:
Time from first dose up to 24 months
Description:
Incidence of adverse events and clinical laboratory abnormalities defined as DLTs. Dose-limiting toxicities included any grade 3 or higher hematologic or nonhematologic toxicity related to conatumumab or the combination of conatumumab with ganitumab except for lymphocytopenia and anemia.
Measure:
Objective Response Rate
TimeFrame:
Time from first dose up to 24 months
Description:
The objective response rate (ORR) is defined as confirmed complete response or partial response using modified Response Evaluation Criteria in Solid Tumors \[RECIST\]: a complete response is the disappearance of all target lesions; a partial response is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Trial Information
NCT ID
NCT00819169
Status
Terminated
Study Type
INTERVENTIONAL
Phases
PHASE1, PHASE2
Sponsor
NantCell, Inc.
Last Updated
December 15, 2025